Astrazeneca (AZN) Ascends While Market Falls: Some Facts to Note

Core Viewpoint - Astrazeneca's stock has shown resilience, outperforming major indices, and is set to report earnings that indicate positive growth expectations for both EPS and revenue [1][2]. Financial Performance - Astrazeneca's upcoming EPS is projected at $1.09, reflecting a 3.81% increase year-over-year [2]. - The Zacks Consensus Estimate for revenue is $15.76 billion, which is a 5.81% increase from the previous year [2]. - For the entire fiscal year, earnings are estimated at $4.59 per share, indicating an 11.68% increase, while revenue is projected to remain flat at $58.73 billion [3]. Analyst Estimates - Recent changes to analyst estimates for Astrazeneca suggest a positive outlook for the company's business operations [4]. - The Zacks Consensus EPS estimate has increased by 0.03% in the past month, and Astrazeneca currently holds a Zacks Rank of 3 (Hold) [6]. Valuation Metrics - Astrazeneca has a Forward P/E ratio of 18.33, which is lower than the industry average of 20.82 [7]. - The company has a PEG ratio of 1.56, compared to the industry average PEG ratio of 1.49 [7]. Industry Context - The Medical - Biomedical and Genetics industry, which includes Astrazeneca, ranks in the top 40% of all industries according to the Zacks Industry Rank [8]. - The top 50% rated industries are shown to outperform the bottom half by a factor of 2 to 1 [8].